NLRP3 and experimental autoimmune encephalomyelitis: For example, by targeting directly to the NATCH domain of NLRP3, MCC950 has been shown to effectively block NLRP3 inflammasome assembly and attenuate the severity of experimental autoimmune encephalomyelitis in a mouse model of multiple sclerosis (5).